Clin Lymphoma Myeloma Leuk. 2022 Oct;pii: S2152-2650(22)01234-4. [Epub ahead of print]22 Suppl 2
S220
Nicole Michmerhuizen,
Bappaditya Chandra,
Hazheen Shirnekhi,
Swarnendu Tripathi,
Brittany Pioso,
David Baggett,
Diana Mitrea,
Ilaria Lacobucci,
Michael White,
Jingjing Chen,
Cheon-Gil Park,
Huiyun Wu,
Stanley Pounds,
Anna Medyukhina,
Khaled Khairy,
Qingsong Gao,
Chunxu Qu,
Scott Gorman,
Simran Bawa,
Carolyn Maslanka,
Swati Kinger,
Priyanka Dogra,
Danika Di Giacomo,
Cristina Mecucci,
Jeffery Klco,
Charles Mullighan,
Richard Kriwacki.
CONTEXT: Rearrangements of the nucleoporin 98 gene (NUP98) define a high-risk subset of childhood acute myeloid leukemia (AML). The resulting fusion oncoproteins (FOs) involve the N-terminal, intrinsically disordered region of NUP98, and the C-terminal portion of one of more than 30 identified fusion partners. Approximately one third of fusion partners have DNA-binding homeodomains, and the remaining partners have other domains involved in gene regulation.OBJECTIVE: NUP98 FOs have long been known to localize in nuclear puncta. Here, we investigated whether these puncta form by liquid-liquid phase separation (LLPS) and how they might contribute to cell transformation.
DESIGN: We first focused on the NUP98::HOXA9 (NHA9) FO, in which the HOXA9 fusion partner includes a DNA-binding homeodomain. We expressed GFP-tagged NHA9 in HEK293T cells and characterized the resulting FO-associated nuclear puncta. We also investigated lentiviral FO expression in mouse hematopoietic stem and progenitor cells (HSPCs), studying localization using confocal imaging, self-renewal using colony forming unit assays, and gene expression using RNA sequencing. We next mutated the phenylalanine glycine (FG) repeats of NUP98 to disrupt interactions with other FOs and interacting proteins or mutated the homeodomain of HOXA9 to disrupt DNA binding. Finally, we investigated the applicability of our findings to other NUP98 FOs with and without homeodomains.
RESULTS: NHA9 localizes in nuclear puncta in HEK293T and HSPCs, and mutation of FG repeats or the HOXA9 homeodomain abrogates puncta formation. Furthermore, expression of NHA9 confers self-renewal, but cell transformation does not occur in FO mutants that fail to form puncta. Upregulation of NUP98 FO target genes, including the HOXA cluster, occurred with expression of NHA9 and transforming, puncta-positive mutants but not in mutant cells that did not form puncta or transform HSPCs. Expression of additional NUP98 FOs (including NUP98::KDM5A, NUP98::LNP1, and NUP98::PRRX1) led to both puncta formation and cell transformation. Finally, cells from a NUP98::KDM5A patient derived xenograft confirmed puncta formation with endogenous FO expression.
CONCLUSIONS: Taken together, these results demonstrate that NUP98 FOs undergo LLPS, show that phase separation is critical for cell transformation and gene expression changes, and provide rationale to further explore the exploitation of NUP98 FO-associated puncta for therapeutical benefit.
Keywords: AML; NUP98; acute myeloid leukemia; fusion oncoprotein; phase separation